IP Library Granted Patent US 8,569,242
Granted Patent B2
US 8,569,242 · App. 13/337,504 · Granted Oct 29, 2013

Method of treating degenerative disorders of the nervous system

Inventor: Katerina Akassoglou (San Francisco, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,569,242
App. No.
13/337,504
Granted
Oct 29, 2013
Kind
B2
Abstract

The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Claims (9)

1. A method for the treatment of a degenerative disorder of the nervous system comprising administering to a subject in need an effective amount of a composition comprising a pharmaceutically acceptable excipient and an antibody that binds a peptide consisting of an amino acid sequence at least 89% identical to SEQ ID NO: 1, wherein said antibody inhibits fibrin γ377-395 (SEQ ID NO:1) specific binding to Mac-1, wherein the degenerative disorder of the nervous system involves leakage of fibrinogen perivascularly in the brain.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is an antigen-binding fragment selected from the group consisting of Fab, Fab′, F(ab′) 2 and F(v).

4. The method of claim 1 , wherein the antibody is chimeric.

5. The method of claim 1 , wherein the antibody is humanized.

6. The method of claim 1 , wherein the degenerative disorder of the nervous system is selected from the group consisting of multiple sclerosis, spinal cord injury, stroke and Alzheimer's Disease.

7. The method of claim 1 , wherein the amino acid sequence is at least 94% identical to SEQ ID NO:1.

8. The method of claim 1 , wherein the amino acid sequence is shown in SEQ ID NO:1.

9. The method of claim 1 , wherein the antibody is a human antibody.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: AKASSOGLOU, KATERINA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 073824/0529 →
CONFIRMATORY LICENSE Recorded Dec 16, 2013
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031820/0254 →
CONFIRMATORY LICENSE Recorded Jul 13, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028553/0768 →
Continuity (4)
Continuation 12896410 · Oct 1, 2010
Division 12067792
Provisional Application 60702218 · Sep 23, 2005
Related Publication 20120093812A1 · Apr 19, 2012